35
edits
Changes
no edit summary
|5
|5
|Abnormality
|Abnormality
|5p
|5p, 5q<ref>{{Cite journal|last=Tirado|first=Carlos A.|last2=Starshak|first2=Phillip|last3=Delgado|first3=Paul|last4=Rao|first4=Nagesh|date=2012-08-20|title="T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach"|url=https://pubmed.ncbi.nlm.nih.gov/23211026|journal=Experimental Hematology & Oncology|volume=1|issue=1|pages=21|doi=10.1186/2162-3619-1-21|issn=2162-3619|pmc=3514161|pmid=23211026}}</ref>
|
|
|Yes
|Yes
|
|Yes
|
|No
|Minor diagnostic criteria
|Minor diagnostic criteria
|-
|-
|Yes
|Yes
|Yes
|Yes
|Yes
|Yes (PARP inhibitors, NCT03263637)
|Deletions of or missense mutations at the ataxia telangiectasia mutated (''ATM'') locus at 11q23 are found in up to 80% to 90% of T-PLL cases. (T-PLL-ISG)
|Deletions of or missense mutations at the ''ATM'' locus are found in up to 80% to 90% of T-PLL cases. (T-PLL-ISG).
|-
|-
|''FBXW10''
|''FBXW10''
|Yes
|Yes
|Yes
|Yes
|Associated with resistance to therapy
|
|The cumulative prevalence of these mutations in T-PLL is approximately 60%. (Dr jaffe book)
|The cumulative prevalence of these mutations in T-PLL is approximately 60%. (Dr jaffe book)
|-
|-
|No
|No
|Yes
|Yes
|Yes??
|See note
|
|EZH2 inhibitors like tazemetostat have shown efficacy in other hematologic malignancies, providing a rationale for their potential use in T-PLL
|-
|-
|''BCOR''
|''BCOR''
|Associated with resistance to therapy
|Associated with resistance to therapy
|Mutations in TP53 are less frequent than deletions<ref>{{Cite journal|last=Stengel|first=Anna|last2=Kern|first2=Wolfgang|last3=Zenger|first3=Melanie|last4=Perglerová|first4=Karolína|last5=Schnittger|first5=Susanne|last6=Haferlach|first6=Torsten|last7=Haferlach|first7=Claudia|date=2016-01|title=Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker|url=https://pubmed.ncbi.nlm.nih.gov/26493028|journal=Genes, Chromosomes & Cancer|volume=55|issue=1|pages=82–94|doi=10.1002/gcc.22313|issn=1098-2264|pmid=26493028}}</ref>
|Mutations in TP53 are less frequent than deletions<ref>{{Cite journal|last=Stengel|first=Anna|last2=Kern|first2=Wolfgang|last3=Zenger|first3=Melanie|last4=Perglerová|first4=Karolína|last5=Schnittger|first5=Susanne|last6=Haferlach|first6=Torsten|last7=Haferlach|first7=Claudia|date=2016-01|title=Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker|url=https://pubmed.ncbi.nlm.nih.gov/26493028|journal=Genes, Chromosomes & Cancer|volume=55|issue=1|pages=82–94|doi=10.1002/gcc.22313|issn=1098-2264|pmid=26493028}}</ref>
|-
|SAMHD1
|
|
|
|
|
|
|
|
|}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
|}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
==Epigenomic Alterations==
==Epigenomic Alterations==